Background/Objectives: This prospective study evaluates the relationship between the ganglion cell–inner plexiform layer (GCIPL), retinal nerve fiber layer (RNFL), and photopic negative response (PhNR) in patients with newly diagnosed pituitary macroadenomas over 12 months. Methods: A total of 40 patients (80 eyes) were included, divided into a treatment group of 27 patients (54 eyes), receiving pharmacological and/or surgical intervention, and an observation group of 13 patients (26 eyes), with non-functional pituitary adenomas (NFPAs) that did not require treatment. Results: Key findings indicate a significant improvement in best corrected visual acuity (BCVA) after 12 months in the treatment group (p= 0.02) and a significant reduction in RNFL thickness in multiple quadrants (p< 0.01). Moreover, PhNR amplitude and W-ratio significantly increased in the treatment group (p< 0.0001). In the observation group, only GCIPL Inferior (p= 0.0470) and PhNR W-ratio (p= 0.0015) showed significant differences. Between-group comparisons showed significant differences in RNFL Nasal quadrant at baseline (p= 0.0017) and after 12 months (p= 0.0150). PhNR amplitude and W-ratio also differed significantly between groups at 12 months (p= 0.0012 andp= 0.0016, respectively). Correlations between OCT and ERG parameters were weak at baseline and diminished over time. Conclusions: These findings suggest that GCIPL, RNFL, and PhNR analyses may be useful for monitoring disease progression and guiding treatment decisions in patients with pituitary macroadenomas.
背景/目的:本研究为前瞻性研究,旨在评估新诊断垂体大腺瘤患者12个月内神经节细胞-内丛状层(GCIPL)、视网膜神经纤维层(RNFL)与明视负向反应(PhNR)之间的关联。方法:共纳入40例患者(80只眼),分为治疗组27例(54只眼),接受药物和/或手术干预;观察组13例(26只眼),为无需治疗的无功能性垂体腺瘤(NFPAs)。结果:关键发现显示治疗组12个月后最佳矫正视力(BCVA)显著改善(p=0.02),多个象限RNFL厚度显著降低(p<0.01)。此外,治疗组PhNR振幅和W比值显著增加(p<0.0001)。观察组仅GCIPL下方厚度(p=0.0470)和PhNR W比值(p=0.0015)出现显著差异。组间比较显示基线期(p=0.0017)和12个月后(p=0.0150)RNFL鼻侧象限存在显著差异。12个月时两组间PhNR振幅与W比值亦呈现显著差异(分别为p=0.0012和p=0.0016)。OCT与ERG参数间的相关性在基线期较弱,并随时间推移进一步减弱。结论:这些发现表明GCIPL、RNFL和PhNR分析可能有助于监测垂体大腺瘤患者的疾病进展并指导治疗决策。